Promoter methylation analysis of CDH1 and p14ARF genes in patients with urothelial bladder cancer
Author(s)
Bayramov, Bayram
Gunes, Sezgin
Buyukalpelli, Recep
Aydın, Oğuz
Henkel, Ralf
Type
Journal Article
Abstract
BACKGROUND/AIM: Urothelial bladder cancer arises from the accumulation of multiple epigenetic and genetic changes. We aimed to investigate the specificity and sensitivity of gene-specific promoter methylation of CDH1 and p14ARF genes in the early diagnosis of bladder cancer and compare those with other diagnostic tests in our population. PATIENTS AND METHODS: In the current study, 65 patients with urothelial bladder cancer and 35 controls without any history of cancer were recruited. Methylation profiles of CDH1 and p14ARF genes from tumor and urine samples were determined by methylation-specific polymerase chain reaction method. RESULTS: Methylation of CDH1 and p14ARF genes in tumor samples was 95.4% and 78.5%, respectively. The methylation frequencies were found to be 68.8% for CDH1 gene and 72.9% for p14ARF gene in urine samples. Sensitivities of CDH1, p14ARF and urine cytology were found to be 67.4%, 72.1% and 34.9%, respectively, while their specificities were 93.9%, 63.6% and 93.9%, respectively. CONCLUSION: Aberrant promoter methylation of CDH1 and p14ARF genes can be used to detect urothelial bladder cancer. In low-grade tumors, when compared with urine cytology, combined methylation analysis of CDH1 and p14ARF genes may not increase the sensitivity to identify malignant cells in urine samples.
Date Issued
2018
Date Acceptance
2018-04-01
Citation
OncoTargets and Therapy, 2018, 11, pp.4189-4196
ISSN
1178-6930
Publisher
Dove Medical Press
Start Page
4189
End Page
4196
Journal / Book Title
OncoTargets and Therapy
Volume
11
Copyright Statement
© 2018 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/30050310
PII: ott-11-4189
Subjects
biomarker
CDH1
p14ARF
urine
urine cytology
urothelial bladder cancer
Publication Status
Published
Coverage Spatial
New Zealand
Date Publish Online
2018-07-19